Due to the recent partnership with AstraZeneca, MSD will now be jointly evaluating Externally Sponsored Research (ESR) proposals with olaparib and selumetinib. Proposals involving selumetinib or olaparib as monotherapy or in combination with drugs other than pembrolizumab should be submitted through the portal on the AstraZeneca website. Proposals involving the combination of olaparib and pembrolizumab should be submitted to MSD.
Proposals involving the combination of selumetinib and pembrolizumab are not currently being accepted.
Clinical Proposal Template
Pre-Clinical Proposal Template (Funding only or Funding and Compound)
Pre-Clinical Material Transfer Proposal Template (Compound only, no Funding)
Pre-Clinical Budget Template
Need Contact Information?